{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:13:17Z","timestamp":1770977597064,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA02812"],"award-info":[{"award-number":["DA02812"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Parker Psychedelics Research Chair at the University of Calgary","award":["Parker Psychedelics Research Chair at the University of Calgary"],"award-info":[{"award-number":["Parker Psychedelics Research Chair at the University of Calgary"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00213-025-06888-7","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:20:49Z","timestamp":1759731649000},"page":"413-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of methamphetamine and 3,4-methylenedioxymethamphetamine on peripheral endocannabinoid concentrations: a study in healthy adults"],"prefix":"10.1007","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4871-3056","authenticated-orcid":false,"given":"Ana","family":"Deutsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor J.","family":"Haggarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin N.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew N.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anya K.","family":"Bershad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-4869","authenticated-orcid":false,"given":"Leah M.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"6888_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/7854_2016_54","volume":"32","author":"SM Aarde","year":"2017","unstructured":"Aarde SM, Taffe MA (2017) Predicting the abuse liability of Entactogen-Class, new and emerging psychoactive substances via preclinical models of drug Self-administration. Curr Top Behav Neurosci 32:145\u2013164. https:\/\/doi.org\/10.1007\/7854_2016_54","journal-title":"Curr Top Behav Neurosci"},{"key":"6888_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.biopsych.2010.08.003","volume":"68","author":"G Bedi","year":"2010","unstructured":"Bedi G, Hyman D, de Wit H (2010) Is ecstasy an \u2018empathogen\u2019? Effects of MDMA on prosocial feelings and identification of emotional States in others. Biol Psychiatry 68:1134\u20131140. https:\/\/doi.org\/10.1016\/j.biopsych.2010.08.003","journal-title":"Biol Psychiatry"},{"key":"6888_CR3","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/s41386-019-0402-z","volume":"44","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Mayo LM, Van Hedger K et al (2019) Effects of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 44:1698\u20131705. https:\/\/doi.org\/10.1038\/s41386-019-0402-z","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"6888_CR4","doi-asserted-by":"publisher","first-page":"108297","DOI":"10.1016\/j.drugalcdep.2020.108297","volume":"217","author":"AR Board","year":"2020","unstructured":"Board AR, Guy G, Jones CM, Hoots B (2020) Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty \u2014 United states, 2014\u20132019. Drug Alcohol Depend 217:108297. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108297","journal-title":"Drug Alcohol Depend"},{"key":"6888_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.phrs.2004.07.009","volume":"51","author":"D Braida","year":"2005","unstructured":"Braida D, Iosu\u00e8 S, Pegorini S, Sala M (2005) 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacol Res 51:177\u2013182. https:\/\/doi.org\/10.1016\/j.phrs.2004.07.009","journal-title":"Pharmacol Res"},{"key":"6888_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","volume":"10","author":"Y Chye","year":"2019","unstructured":"Chye Y, Christensen E, Solowij N, Y\u00fccel M (2019) The endocannabinoid system and cannabidiol\u2019s promise for the treatment of substance use disorder. Front Psychiatry 10:63. https:\/\/doi.org\/10.3389\/fpsyt.2019.00063","journal-title":"Front Psychiatry"},{"key":"6888_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2017.04.033","volume":"124","author":"D Covey","year":"2017","unstructured":"Covey D, Mateo Y, Sulzer D et al (2017) Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology 124:52\u201361. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.04.033","journal-title":"Neuropharmacology"},{"key":"6888_CR8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/j.1360-0443.2009.02564.x","volume":"104","author":"CC Cruickshank","year":"2009","unstructured":"Cruickshank CC, Dyer KR (2009) A review of the clinical Pharmacology of methamphetamine. Addict Abingdon Engl 104:1085\u20131099. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02564.x","journal-title":"Addict Abingdon Engl"},{"key":"6888_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","volume":"43","author":"C de Meneses-Gaya","year":"2020","unstructured":"de Meneses-Gaya C, Crippa JA, Hallak JE et al (2020) Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Braz J Psychiatry 43:467\u2013476. https:\/\/doi.org\/10.1590\/1516-4446-2020-1416","journal-title":"Braz J Psychiatry"},{"key":"6888_CR10","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946\u20131949. https:\/\/doi.org\/10.1126\/science.1470919","journal-title":"Science"},{"key":"6888_CR11","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1002\/jcph.1918","volume":"61","author":"JR Docherty","year":"2021","unstructured":"Docherty JR, Alsufyani HA (2021) Pharmacology of drugs used as stimulants. J Clin Pharmacol 61:S53\u2013S69. https:\/\/doi.org\/10.1002\/jcph.1918","journal-title":"J Clin Pharmacol"},{"key":"6888_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00213-017-4650-5","volume":"235","author":"PC Dolder","year":"2018","unstructured":"Dolder PC, M\u00fcller F, Schmid Y et al (2018) Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology 235:467\u2013479. https:\/\/doi.org\/10.1007\/s00213-017-4650-5","journal-title":"Psychopharmacology"},{"key":"6888_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/00952990.2025.2456499","volume":"51","author":"GO Elliott","year":"2025","unstructured":"Elliott GO, Petrie GN, Kroll SL et al (2025) Changes in peripheral endocannabinoid levels in substance use disorders: a review of clinical evidence. Am J Drug Alcohol Abuse 51:152\u2013164. https:\/\/doi.org\/10.1080\/00952990.2025.2456499","journal-title":"Am J Drug Alcohol Abuse"},{"key":"6888_CR14","doi-asserted-by":"publisher","first-page":"108625","DOI":"10.1016\/j.neuropharm.2021.108625","volume":"193","author":"SA Engi","year":"2021","unstructured":"Engi SA, Beebe EJ, Ayvazian VM et al (2021) Cocaine-induced increases in motivation require 2-arachidonoylglycerol mobilization and CB1 receptor activation in the ventral tegmental area. Neuropharmacology 193:108625. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108625","journal-title":"Neuropharmacology"},{"key":"6888_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1089\/can.2023.0065","volume":"8","author":"JAB Fernandes","year":"2023","unstructured":"Fernandes JAB, Filev R, Fidalgo TM (2023) Cannabinoids for substance use disorder treatment: what does the current evidence say?? Cannabis Cannabinoid Res 8:703\u2013715. https:\/\/doi.org\/10.1089\/can.2023.0065","journal-title":"Cannabis Cannabinoid Res"},{"key":"6888_CR16","doi-asserted-by":"publisher","unstructured":"Gallassi AD, de Oliveira AWC, Rodrigues LA et al (2024) Cannabidiol compared to pharmacological treatment as usual for crack use disorder: a feasibility, preliminary efficacy, parallel, double-blind, randomized clinical trial. Int J Ment Health Addict 1\u201325. https:\/\/doi.org\/10.1007\/s11469-024-01287-z","DOI":"10.1007\/s11469-024-01287-z"},{"key":"6888_CR17","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.3390\/ijerph20054087","volume":"20","author":"KA Gharbi","year":"2023","unstructured":"Gharbi KA, Bonomo YA, Hallinan CM (2023) Evidence from human studies for utilising cannabinoids for the treatment of Substance-Use disorders: A scoping review with a systematic approach. Int J Environ Res Public Health 20:4087. https:\/\/doi.org\/10.3390\/ijerph20054087","journal-title":"Int J Environ Res Public Health"},{"key":"6888_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/0091-3057(91)90137-Q","volume":"39","author":"B Gough","year":"1991","unstructured":"Gough B, Ali SF, Slikker W, Holson RR (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 39:619\u2013623. https:\/\/doi.org\/10.1016\/0091-3057(91)90137-Q","journal-title":"Pharmacol Biochem Behav"},{"key":"6888_CR19","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1111\/ejn.16346","volume":"59","author":"CJ Haggarty","year":"2024","unstructured":"Haggarty CJ, Bershad AK, Kumar MK et al (2024) The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli. Eur J Neurosci 59:3224\u20133235. https:\/\/doi.org\/10.1111\/ejn.16346","journal-title":"Eur J Neurosci"},{"key":"6888_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00213-017-4787-2","volume":"235","author":"E Haijen","year":"2018","unstructured":"Haijen E, Farre M, de la Torre R et al (2018) Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. Psychopharmacology 235:709\u2013717. https:\/\/doi.org\/10.1007\/s00213-017-4787-2","journal-title":"Psychopharmacology"},{"key":"6888_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1038\/sj.npp.1300223","volume":"28","author":"DS Harris","year":"2003","unstructured":"Harris DS, Reus VI, Wolkowitz OM et al (2003) Altering cortisol level does not change the pleasurable effects of methamphetamine in humans. Neuropsychopharmacology 28:1677\u20131684. https:\/\/doi.org\/10.1038\/sj.npp.1300223","journal-title":"Neuropsychopharmacology"},{"key":"6888_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.biopsych.2013.09.005","volume":"75","author":"G Hernandez","year":"2014","unstructured":"Hernandez G, Oleson EB, Gentry RN et al (2014) Endocannabinoids promote cocaine-induced impulsivity and its rapid dopaminergic correlates. Biol Psychiatry 75:487\u2013498. https:\/\/doi.org\/10.1016\/j.biopsych.2013.09.005","journal-title":"Biol Psychiatry"},{"key":"6888_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.psyneuen.2011.09.017","volume":"37","author":"E Heyman","year":"2012","unstructured":"Heyman E, Gamelin F-X, Goekint M et al (2012) Intense exercise increases Circulating endocannabinoid and BDNF levels in humans\u2013possible implications for reward and depression. Psychoneuroendocrinology 37:844\u2013851. https:\/\/doi.org\/10.1016\/j.psyneuen.2011.09.017","journal-title":"Psychoneuroendocrinology"},{"key":"6888_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.psyneuen.2009.03.013","volume":"34","author":"MN Hill","year":"2009","unstructured":"Hill MN, Miller GE, Carrier EJ et al (2009) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34:1257\u20131262. https:\/\/doi.org\/10.1016\/j.psyneuen.2009.03.013","journal-title":"Psychoneuroendocrinology"},{"key":"6888_CR25","doi-asserted-by":"publisher","first-page":"14980","DOI":"10.1523\/JNEUROSCI.4283-10.2010","volume":"30","author":"MN Hill","year":"2010","unstructured":"Hill MN, Patel S, Campolongo P et al (2010) Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 30:14980\u201314986. https:\/\/doi.org\/10.1523\/JNEUROSCI.4283-10.2010","journal-title":"J Neurosci"},{"key":"6888_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/npp.2017.130","volume":"43","author":"CJ Hillard","year":"2018","unstructured":"Hillard CJ (2018) Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology 43:155\u2013172. https:\/\/doi.org\/10.1038\/npp.2017.130","journal-title":"Neuropsychopharmacology"},{"key":"6888_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F, Vizeli P, M\u00fcller F et al (2020) Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology 45:462\u2013471. https:\/\/doi.org\/10.1038\/s41386-019-0569-3","journal-title":"Neuropsychopharmacology"},{"key":"6888_CR28","first-page":"917","volume":"165","author":"H Kalant","year":"2001","unstructured":"Kalant H (2001) The Pharmacology and toxicology of ecstasy (MDMA) and related drugs. CMAJ 165:917\u2013928","journal-title":"CMAJ"},{"key":"6888_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00213-011-2383-4","volume":"219","author":"MG Kirkpatrick","year":"2012","unstructured":"Kirkpatrick MG, Gunderson EW, Perez AY et al (2012) A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 219:109\u2013122. https:\/\/doi.org\/10.1007\/s00213-011-2383-4","journal-title":"Psychopharmacology"},{"key":"6888_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-023-02628-7","volume":"13","author":"SL Kroll","year":"2023","unstructured":"Kroll SL, Hulka LM, Kexel A-K et al (2023) Plasma endocannabinoids in cocaine dependence and their relation to cerebral metabotropic glutamate receptor 5 density. Transl Psychiatry 13:1\u201310. https:\/\/doi.org\/10.1038\/s41398-023-02628-7","journal-title":"Transl Psychiatry"},{"key":"6888_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.9740\/mhc.2021.11.347","volume":"11","author":"MT Liu","year":"2021","unstructured":"Liu MT (2021) Pharmacotherapy treatment of stimulant use disorder. Ment Health Clin 11:347\u2013357. https:\/\/doi.org\/10.9740\/mhc.2021.11.347","journal-title":"Ment Health Clin"},{"key":"6888_CR32","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","volume":"22","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B et al (2021) The endocannabinoid system: A potential target for the treatment of various diseases. Int J Mol Sci 22:9472. https:\/\/doi.org\/10.3390\/ijms22179472","journal-title":"Int J Mol Sci"},{"key":"6888_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.tins.2006.01.008","volume":"29","author":"R Maldonado","year":"2006","unstructured":"Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225\u2013232. https:\/\/doi.org\/10.1016\/j.tins.2006.01.008","journal-title":"Trends Neurosci"},{"key":"6888_CR34","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1046\/j.1460-9568.2000.00287.x","volume":"12","author":"M Martin","year":"2000","unstructured":"Martin M, Ledent C, Parmentier M et al (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12:4038\u20134046. https:\/\/doi.org\/10.1046\/j.1460-9568.2000.00287.x","journal-title":"Eur J Neurosci"},{"issue":"1-2","key":"6888_CR61","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neulet.2006.03.055","volume":"402","author":"Rebeca Mart\u00ednez-Turrillas","year":"2006","unstructured":"Mart\u00ednez-Turrillas R, Moyano S, Del R\u00edo J, Frechilla D (2006) Differential effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d) on BDNF mRNA expression in rat frontal cortex and hippocampus. Neurosci Lett 402:126\u2013130. https:\/\/doi.org\/10.1016\/j.neulet.2006.03.055","journal-title":"Neuroscience Letters"},{"key":"6888_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-d","volume":"50","author":"R Mechoulam","year":"1995","unstructured":"Mechoulam R, Ben-Shabat S, Hanus L et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83\u201390. https:\/\/doi.org\/10.1016\/0006-2952(95)00109-d","journal-title":"Biochem Pharmacol"},{"key":"6888_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40478-024-01864-2","volume":"12","author":"P Meier","year":"2024","unstructured":"Meier P, Glasmacher S, Salmen A et al (2024) Comparative targeted lipidomics between serum and cerebrospinal fluid of multiple sclerosis patients shows sex and age-specific differences of endocannabinoids and glucocorticoids. Acta Neuropathol Commun 12:160. https:\/\/doi.org\/10.1186\/s40478-024-01864-2","journal-title":"Acta Neuropathol Commun"},{"key":"6888_CR37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A et al (2021) MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27:1025\u20131033. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"key":"6888_CR38","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B et al (2023) MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29:2473\u20132480. https:\/\/doi.org\/10.1038\/s41591-023-02565-4","journal-title":"Nat Med"},{"key":"6888_CR39","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/add.15417","volume":"116","author":"V Mongeau-P\u00e9russe","year":"2021","unstructured":"Mongeau-P\u00e9russe V, Brissette S, Bruneau J et al (2021) Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. Addiction 116:2431\u20132442. https:\/\/doi.org\/10.1111\/add.15417","journal-title":"Addiction"},{"key":"6888_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00213-012-2954-z","volume":"227","author":"ME Morean","year":"2012","unstructured":"Morean ME, de Wit H, King AC et al (2012) The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology 227:177. https:\/\/doi.org\/10.1007\/s00213-012-2954-z","journal-title":"Psychopharmacology"},{"key":"6888_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fnint.2014.00022","volume":"8","author":"A Palomino","year":"2014","unstructured":"Palomino A, Pav\u00f3n F-J, Blanco-Calvo E et al (2014) Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum. Front Integr Neurosci 8:22. https:\/\/doi.org\/10.3389\/fnint.2014.00022","journal-title":"Front Integr Neurosci"},{"key":"6888_CR42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrn4004","volume":"16","author":"LH Parsons","year":"2015","unstructured":"Parsons LH, Hurd YL (2015) Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci 16:579\u2013594. https:\/\/doi.org\/10.1038\/nrn4004","journal-title":"Nat Rev Neurosci"},{"key":"6888_CR43","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/jpet.103.054270","volume":"306","author":"S Patel","year":"2003","unstructured":"Patel S, Rademacher DJ, Hillard CJ (2003) Differential regulation of the endocannabinoids Anandamide and 2-Arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 306:880\u2013888. https:\/\/doi.org\/10.1124\/jpet.103.054270","journal-title":"J Pharmacol Exp Ther"},{"key":"6888_CR44","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/adb.12107","volume":"18","author":"FJ Pav\u00f3n","year":"2013","unstructured":"Pav\u00f3n FJ, Araos P, Pastor A et al (2013) Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. Addict Biol 18:955\u2013969. https:\/\/doi.org\/10.1111\/adb.12107","journal-title":"Addict Biol"},{"key":"6888_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.phrs.2017.03.009","volume":"120","author":"MD Prakash","year":"2017","unstructured":"Prakash MD, Tangalakis K, Antonipillai J et al (2017) Methamphetamine: effects on the brain, gut and immune system. Pharmacol Res 120:60\u201367. https:\/\/doi.org\/10.1016\/j.phrs.2017.03.009","journal-title":"Pharmacol Res"},{"key":"6888_CR46","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/rcm.7277","volume":"29","author":"M Qi","year":"2015","unstructured":"Qi M, Morena M, Vecchiarelli HA et al (2015) A robust capillary liquid chromatography\/tandem mass spectrometry method for quantitation of neuromodulatory endocannabinoids. Rapid Commun Mass Spectrom RCM 29:1889\u20131897. https:\/\/doi.org\/10.1002\/rcm.7277","journal-title":"Rapid Commun Mass Spectrom RCM"},{"key":"6888_CR47","volume-title":"Methamphetamine toxicity","author":"JR Richards","year":"2025","unstructured":"Richards JR, Laurin EG (2025) Methamphetamine toxicity. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"6888_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3109\/10253890.2011.586753","volume":"14","author":"CJ Riebe","year":"2011","unstructured":"Riebe CJ, Wotjak CT (2011) Endocannabinoids and stress. Stress Amst Neth 14:384\u2013397. https:\/\/doi.org\/10.3109\/10253890.2011.586753","journal-title":"Stress Amst Neth"},{"key":"6888_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejphar.2003.08.054","volume":"479","author":"RB Rothman","year":"2003","unstructured":"Rothman RB, Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479:23\u201340. https:\/\/doi.org\/10.1016\/j.ejphar.2003.08.054","journal-title":"Eur J Pharmacol"},{"key":"6888_CR50","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.neubiorev.2010.12.010","volume":"35","author":"S Schenk","year":"2011","unstructured":"Schenk S (2011) MDMA (ecstasy) abuse as an example of dopamine neuroplasticity. Neurosci Biobehav Rev 35:1203\u20131218. https:\/\/doi.org\/10.1016\/j.neubiorev.2010.12.010","journal-title":"Neurosci Biobehav Rev"},{"key":"6888_CR51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2010.02.005","volume":"633","author":"CW Schindler","year":"2010","unstructured":"Schindler CW, Panlilio LV, Gilman JP et al (2010) Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys. Eur J Pharmacol 633:44\u201349. https:\/\/doi.org\/10.1016\/j.ejphar.2010.02.005","journal-title":"Eur J Pharmacol"},{"key":"6888_CR52","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.addbeh.2017.04.006","volume":"72","author":"ME Soc\u00edas","year":"2017","unstructured":"Soc\u00edas ME, Kerr T, Wood E et al (2017) Intentional cannabis use to reduce crack cocaine use in a Canadian setting: A longitudinal analysis. Addict Behav 72:138\u2013143. https:\/\/doi.org\/10.1016\/j.addbeh.2017.04.006","journal-title":"Addict Behav"},{"key":"6888_CR53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.anclin.2023.09.003","volume":"42","author":"W Song","year":"2024","unstructured":"Song W, Simona A, Zhang P et al (2024) Stimulant drugs and stimulant use disorder. Anesthesiol Clin 42:103\u2013115. https:\/\/doi.org\/10.1016\/j.anclin.2023.09.003","journal-title":"Anesthesiol Clin"},{"key":"6888_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41386-024-01972-6","volume":"50","author":"I Straumann","year":"2024","unstructured":"Straumann I, Avedisian I, Klaiber A et al (2024) Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 50:362\u2013371. https:\/\/doi.org\/10.1038\/s41386-024-01972-6","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"6888_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/15622975.2025.2502394","volume":"26","author":"RD Topuz","year":"2025","unstructured":"Topuz RD et al (2025) Do serum endocannabinoid and N-acylethanolamine concentrations reflect their brain levels in two different rat stress models? World J Biol Psychiatry 26:199\u2013210. https:\/\/doi.org\/10.1080\/15622975.2025.2502394","journal-title":"World J Biol Psychiatry"},{"key":"6888_CR56","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","volume":"189","author":"CD Verrico","year":"2007","unstructured":"Verrico CD, Miller GM, Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189:489\u2013503. https:\/\/doi.org\/10.1007\/s00213-005-0174-5","journal-title":"Psychopharmacology"},{"key":"6888_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/wps.21073","volume":"22","author":"ND Volkow","year":"2023","unstructured":"Volkow ND, Blanco C (2023) Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry 22:203\u2013229. https:\/\/doi.org\/10.1002\/wps.21073","journal-title":"World Psychiatry"},{"key":"6888_CR59","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.celrep.2015.08.041","volume":"12","author":"H Wang","year":"2015","unstructured":"Wang H, Treadway T, Covey DP et al (2015) Cocaine-Induced endocannabinoid mobilization in the ventral tegmental area. Cell Rep 12:1997\u20132008. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.041","journal-title":"Cell Rep"},{"key":"6888_CR58","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00213-006-0599-5","volume":"189","author":"Z Wang","year":"2007","unstructured":"Wang Z, Woolverton WL (2007) Estimating the relative reinforcing strength of (+\/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology 189:483\u2013488. https:\/\/doi.org\/10.1007\/s00213-006-0599-5","journal-title":"Psychopharmacology"},{"key":"6888_CR60","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0091-3057(02)00818-3","volume":"73","author":"TL White","year":"2002","unstructured":"White TL, Justice AJH, de Wit H (2002) Differential subjective effects of d-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73:729\u2013741. https:\/\/doi.org\/10.1016\/S0091-3057(02)00818-3","journal-title":"Pharmacol Biochem Behav"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06888-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:22:12Z","timestamp":1770974532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06888-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["6888"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06888-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the University of Chicago internal review board and all procedures were completed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants provided informed consent to participate and publish resulting data during the first visit to the laboratory.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"This research was supported by USPHS DA02812 (Harriet de Wit) and the Parker Psychedelic Research Chair at the University of Calgary (Leah Mayo).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}